




COMPLETE



# NUTIDE:301

SOLID TUMOR - PHASE 1 STUDY

## Designed to assess the safety of NUC-3373



Number of patients

**59**

Part 1 (n= 43)  
Part 2 (n= 16)

Age (median)

**59**

(range 20-77)

Prior chemotherapy regimens (median)

**3**

(range 0-11)

Sex	Male	37 (60%)
	Female	25 (40%)
ECOG PS	0	30 (48%)
	1	32 (52%)
Cancer type	CRC	28 (45%)
	Esophago-gastric	6 (10%)
	Pancreas	4 (6%)
	Other	24 (39%)
Prior fluoropyrimidine	Yes	46 (74%)
	No	16 (26%)

62 patients enrolled, 59 patients treated

Spiliopoulou et al (2021) Ann Oncol; 32: Suppl 5 Abstract ID 549P (ESMO September 2021)  
Spiliopoulou et al (2024) J Exp Clin Cancer Res 43, 100

## Favorable safety profile


- NUC-3373 was well tolerated in patients who had exhausted all other therapeutic options
- No Grade 4 toxicities
- Low rates of Grade 3 toxicities
- MTD 2500 mg/m<sup>2</sup>

	NUC-3373 (n=59)		
	Grade 1 & 2, n(%)	Grade 3, n(%)	Grade 4, n(%)
Fatigue	26 (44%)	1 (2%)	0
Nausea	21 (36%)	0	0
Diarrhea	18 (31%)	0	0
Infusion reaction	17 (29%)	0	0
Transaminases increased	7 (12%)	4 (7%)	0
Anemia	9 (15%)	0	0
Vomiting	9 (15%)	0	0
Constipation	7 (12%)	0	0

\*Treatment-related adverse events (all grades) that occurred in >10% of patients

Data cut-off: March 18, 2022

## Attractive pharmacokinetic profile



- Long half-life of NUC 3373 compared to 5-FU (up to 10 hours vs 8-14 minutes)
- Dose-proportional increase in NUC-3373 Area Under the Curve (AUC) was observed across the concentration range

## Encouraging signs of efficacy in patients who had exhausted all other therapies



70 YRS

### Metastatic Colorectal Cancer

Prior lines of therapy

1. 5-FU based chemoradiotherapy (adjuvant)
2. FOLFOX: for metastatic disease
3. CAPOX: progressed within 2 months
4. FOLFIRI: progressed within 8 months
5. LONSURF: progressed within 3 months
6. Irinotecan: treatment for 1 month

**NUC-3373 1500 mg/m<sup>2</sup> Q1W**  
Stable Disease 9 months



55 YRS

### Metastatic Basal Cell Carcinoma

Prior lines of therapy

1. Vismodegib: treatment for 11 months
2. Paclitaxel + carboplatin: treatment for 3 months

**NUC-3373 1500 mg/m<sup>2</sup> Q2W**  
Stable disease 10 months



60 YRS

### Metastatic Cholangiocarcinoma

Prior line of therapy

1. Cisplatin + gemcitabine: progressed within 6 months

**NUC-3373 1125 mg/m<sup>2</sup> Q1W**  
Stable disease 11 months

## Key takeaways

**NUC-3373 has shown encouraging signs of anti-cancer activity; including in 5-FU resistant patients**

**Recommended Phase 2 dose as monotherapy is 2500 mg/m<sup>2</sup> Q1W**